Literature DB >> 26857002

[Surgery for metastases, anatomical and ethical limits. Special aspect: oligometastases].

A Perrakis1, T A Juratli2, W Hohenberger3, R S Croner3, G Schackert4.   

Abstract

The surgical resection of metastases is nowadays feasible in selected patients with multifocal metastatic disease due to the implementation of interdisciplinary multimodal therapeutic options. Anatomical limitations do not seem to represent obstacles which cannot be overcome because of the development of new surgical techniques. The cornerstone of the selection of patients is the correct staging diagnosis achieved through modern diagnostic tools; however, surgery alone does not always offer acceptable survival and recurrence-free rates. Furthermore, in every complex surgical procedure there is the risk of morbidity and mortality; therefore, parameters such as alternative therapeutic modalities, the individual situation of the patient and tumor biology have to be considered in order to make the correct selection of patients. This is one of the major future challenges and should never be driven by unfounded hopes and expectations of the patients. The same principle also applies for brain metastases, which represent the most common brain tumors. Approximately 70 % of patients with brain metastases have 1-3 lesions (oligometastases). Treatment is now individualized and the goal of therapy has shifted towards long-term survival (≥ 24 months) and improved quality of life. Under this aspect surgery is one of the important treatment options, particularly in patients with a single metastasis or oligometastases. Furthermore, approximately 20 % of patients who have recurrent brain metastases, successfully undergo a complete resection of tumors and with a Karnofsky performance status (KPS) score > 70 show a long-term survival of ≥ 24 months.

Entities:  

Keywords:  Chemotherapy; Ethics; Limitations; Oligometastases; Surgery

Mesh:

Year:  2016        PMID: 26857002     DOI: 10.1007/s00104-015-0147-0

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  64 in total

1.  Part II: Surgery versus radiosurgery for brain metastasis: surgical advantages and radiosurgical myths.

Authors:  Amos O Dare; Raymond Sawaya
Journal:  Clin Neurosurg       Date:  2004

2.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2013-10-11       Impact factor: 41.316

3.  Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect.

Authors:  Dominique Elias; Gabriel Liberale; Déwi Vernerey; Marc Pocard; Michel Ducreux; Valérie Boige; David Malka; Jean-Pierre Pignon; Philippe Lasser
Journal:  Ann Surg Oncol       Date:  2005-09-26       Impact factor: 5.344

4.  Simultaneous detection of colorectal carcinoma liver and lung metastases does not warrant resection.

Authors:  S Nagakura; Y Shirai; Y Yamato; N Yokoyama; T Suda; K Hatakeyama
Journal:  J Am Coll Surg       Date:  2001-08       Impact factor: 6.113

5.  Colorectal metastases to the liver: present status of management.

Authors:  M Lise; P P Da Pian; D Nitti; P L Pilati; C Prevaldi
Journal:  Dis Colon Rectum       Date:  1990-08       Impact factor: 4.585

6.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

7.  Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma.

Authors:  Tommaso Claudio Mineo; Vincenzo Ambrogi; Giuseppe Tonini; Patrizio Bollero; Mario Roselli; Davide Mineo; Italo Nofroni
Journal:  J Am Coll Surg       Date:  2003-09       Impact factor: 6.113

8.  Distribution of brain metastases.

Authors:  J Y Delattre; G Krol; H T Thaler; J B Posner
Journal:  Arch Neurol       Date:  1988-07

9.  Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center.

Authors:  Alessandra Fabi; Alessandra Felici; Giulio Metro; Alessandra Mirri; Emilio Bria; Stefano Telera; Luca Moscetti; Michelangelo Russillo; Gaetano Lanzetta; Giovanni Mansueto; Andrea Pace; Marta Maschio; Antonello Vidiri; Isabella Sperduti; Francesco Cognetti; Carmine M Carapella
Journal:  J Exp Clin Cancer Res       Date:  2011-01-18

Review 10.  The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Mario Ammirati; Charles S Cobbs; Mark E Linskey; Nina A Paleologos; Timothy C Ryken; Stuart H Burri; Anthony L Asher; Jay S Loeffler; Paula D Robinson; David W Andrews; Laurie E Gaspar; Douglas Kondziolka; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Roy A Patchell; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.